WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) recently reported its full-year 2025 financial results and outlined progress across its QTORIN drug development pipeline, including plans to submit a new drug application in the second half of 2026, the company said.
The clinical-stage biopharmaceutical company said it is advancing QTORIN rapamycin for microcystic lymphatic malformations, with a regulatory submission on track following positive Phase 3 trial results.
According to the company, the Phase 3 SELVA study met its primary endpoint, showing statistically significant improvement in patients, with 95% of participants demonstrating improvement at 24 weeks. The treatment was reported to be well tolerated, with no drug-related serious adverse events.
Palvella said it submitted a request for a pre-NDA meeting with the U.S. Food and Drug Administration in March, with the meeting expected in the second quarter of 2026.
The company is also preparing for a potential U.S. commercial launch of the therapy, which targets a rare condition affecting more than 30,000 diagnosed patients in the United States and currently has no FDA-approved treatments.
In addition, Palvella reported positive Phase 2 results for QTORIN rapamycin in treating cutaneous venous malformations, with 73% of trial participants showing improvement. The company plans to initiate a Phase 3 trial for that indication in the second half of 2026.
The company said it also plans to begin a Phase 2 trial in the second quarter of 2026 for QTORIN rapamycin to treat clinically significant angiokeratomas, a condition affecting more than 50,000 diagnosed U.S. patients.
Another Phase 2 trial is planned for the second half of 2026 for QTORIN pitavastatin, a separate product candidate targeting disseminated superficial actinic porokeratosis, a genetic skin disorder with no approved treatments.
Palvella said it expects to expand the QTORIN platform into additional indications and plans to announce another clinical indication and a new product candidate later in 2026.
On the corporate side, the company reported completing a public stock offering that generated $230.0 million in gross proceeds and strengthened its leadership team with two executive appointments.
For the year ended December 31, 2025, Palvella reported research and development expenses of $22.8 million, up from $8.2 million in 2024, primarily due to clinical trial activity. General and administrative expenses rose to $15.8 million from $5.9 million, driven by increased staffing and public company costs.
Net loss attributable to common stockholders was $41.7 million, or $3.71 per share, compared with a net loss of $17.4 million, or $7.83 per share, in 2024.
The company reported pro forma cash of approximately $274 million as of December 31, 2025, including proceeds from a February 2026 equity financing, with cash and cash equivalents of $58.0 million at year-end.
Shares outstanding totaled 15,708,420 as of March 25, 2026, including common stock and equivalents.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.